These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 8312047)

  • 1. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.
    Wild C; Greenwell T; Matthews T
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1051-3. PubMed ID: 8312047
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 4. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.
    Muñoz-Barroso I; Durell S; Sakaguchi K; Appella E; Blumenthal R
    J Cell Biol; 1998 Jan; 140(2):315-23. PubMed ID: 9442107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein.
    Slepushkin VA; Kornilaeva GV; Andreev SM; Sidorova MV; Petrukhina AO; Matsevich GR; Raduk SV; Grigoriev VB; Makarova TV; Lukashov VV
    Virology; 1993 May; 194(1):294-301. PubMed ID: 7683157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.
    Wang C; Lu L; Na H; Li X; Wang Q; Jiang X; Xu X; Yu F; Zhang T; Li J; Zhang Z; Zheng B; Liang G; Cai L; Jiang S; Liu K
    J Med Chem; 2014 Sep; 57(17):7342-54. PubMed ID: 25156906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
    Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
    AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
    Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
    Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
    Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.
    Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E
    Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 inhibition by a peptide.
    Jiang S; Lin K; Strick N; Neurath AR
    Nature; 1993 Sep; 365(6442):113. PubMed ID: 8371754
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.
    González-Ortega E; Ballana E; Badia R; Clotet B; Esté JA
    Antiviral Res; 2011 Dec; 92(3):479-83. PubMed ID: 22027647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence.
    Jiang S; Lin K
    Pept Res; 1995; 8(6):345-8. PubMed ID: 8838418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
    Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
    J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants.
    Holguín A; De Arellano ER; Soriano V
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1067-74. PubMed ID: 17919099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
    Lohrengel S; Hermann F; Hagmann I; Oberwinkler H; Scrivano L; Hoffmann C; von Laer D; Dittmar MT
    J Virol; 2005 Aug; 79(16):10237-46. PubMed ID: 16051817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.
    Wild C; Greenwell T; Shugars D; Rimsky-Clarke L; Matthews T
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):323-5. PubMed ID: 7786578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.